micro-community-banner
 
  • Saved

1yr
Myofilament dysfunction in diastolic heart failure - PubMed

Myofilament dysfunction in diastolic heart failure - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37837495/

Diastolic heart failure (DHF), in which impaired ventricular filling leads to typical heart failure symptoms, represents over 50% of all heart failure cases and is linked with risk factors, including...

Diastolic heart failure (DHF) involves impaired ventricular filling despite preserved systolic function. Exploring its molecular mechanisms can address knowledge gaps, highlight determinants of diastolic dysfunction, and guide novel therapeutic strategies.

  • Saved

1yr
Treatment Strategies for Chronic Coronary Heart Disease with Left Ventricular Systolic Dysfunction or Preserved Ejection Fraction-A Systematic Review and Meta-Analysis - PubMed

Treatment Strategies for Chronic Coronary Heart Disease with Left Ventricular Systolic Dysfunction or Preserved Ejection Fraction-A Systematic Review and Meta-Analysis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38133147/

In individuals diagnosed with chronic CHD and preserved LV EF, the initial invasive approach did not demonstrate a clinical advantage over OMT. Conversely, in patients with ischemic LV systolic dysfunction,...

In chronic CHD, invasive strategies offer no advantage over OMT for preserved LV function but improve survival and reduce CV events in patients with ischemic LV systolic dysfunction.

  • Saved

1yr

Did you know?  Parallelizing diagnostic processes can significantly shorten production timelines, benefiting both patients and healthcare professionals. Faster diagnoses lead to earlier treatment initiation, reducing uncertainty and improving patient outcomes. Additionally, quicker treatment times result in faster recovery, making the entire care pathway more efficient for everyone involved.

How can streamlining diagnostic processes further improve patient recovery times and enhance the efficiency of healthcare teams?

background

How can streamlining diagnostic processes further improve patient recovery times and enhance the efficiency of healthcare teams?

  • Saved

1yr
Addressing heart failure risk in a 54-Year-old male with type 2 diabetes

Initial Complaints: A 54-year-old male, presented with fatigue, mild shortness of breath, and occasional ankle swelling.

Brief History: His medical history includes well-controlled type 2 diabetes mellitus (T2D), hypertension, and obesity (BMI 32 kg/m²). He has no prior history of coronary artery disease or myocardial infarction, but both parents had heart disease.

Clinical Examination: Physical examination revealed bilateral ankle edema, jugular venous distension, and slightly elevated blood pressure (140/90 mmHg).

His weight was 110 kg, and heart sounds were regular with no murmurs. Symptoms included shortness of breath on exertion, likely exacerbated by obesity.

Diagnostic Workup: Echocardiography showed preserved left ventricular ejection fraction (LVEF) of 68%, indicating normal pump function. However, global longitudinal strain (GLS) was -16%, suggesting subclinical left ventricular dysfunction likely due to long-standing hypertension, diabetes, and obesity.

Laboratory Results: Routine blood tests indicated HbA1c at 6.8%. Kidney function was normal (eGFR 72 mL/min/1.73 m²). N-terminal pro-brain natriuretic peptide (NT-proBNP) levels were slightly elevated, indicating cardiac stress. The lipid panel revealed elevated triglycerides and borderline high LDL cholesterol.

  1. What is the patient’s diagnosis based on the presented symptoms and diagnostic findings?
  2. What percentage of patients with heart failure also have obesity-related complications?
  3. What are the next steps in management for this patient?

Show More Comments

  • Saved

1yr
Innovative Cardiovascular Research Insights at AHA’s 100th Anniversary

At the American Heart Association’s centennial conference, Dr. Amit Khera, Director of Preventive Cardiology and Professor at UT Southwestern Medical Center, and Dr. John L. Sapp, Assistant Dean of Clinical Research at Dalhousie University, presented key findings. Topics included Tirzepatide’s impact on HFpEF and obesity, the comparison of left atrial appendage closure versus anticoagulation for atrial fibrillation, intensive blood pressure control in diabetes, and insights from the VANISH2 trial on ventricular tachycardia. These findings provide healthcare professionals with evidence-based strategies to advance cardiovascular care.